References
- GisbertJPPanésJLoss of response and requirement of infliximab dose intensification in Crohn’s disease: a reviewAm J Gastroenterol2009104376076719174781
- BillioudVSandbornWJPeyrin-BirouletLLoss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic reviewAm J Gastroenterol2011106467468421407178
- OtakeHMatsumotoSMashimaHDoes long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort studyMedicine20179616e663528422861
- TillackCEhmannLMFriedrichMAnti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatmentGut201463456757723468464
- PuglieseDGuidiLFerraroPMParadoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up studyAliment Pharmacol Ther201542788088826235565
- RahierJFBucheSPeyrin-BirouletLSevere skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapyClin Gastroenterol Hepatol20108121048105520728573
- Ramos-CasalsMBrito-ZerónPMuñozSAutoimmune diseases induced by TNF-targeted therapies: analysis of 233 casesMedicine200786424225117632266
- WollinaUHanselGKochASchönlebeJKöstlerEHaroskeGTumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patientsAm J Clin Dermatol20089111418092839
- EphgraveKExtra-intestinal manifestations of Crohn’s diseaseSurg Clin North Am200787367368017560419
- ShorbagiABayraktarYPrimary sclerosing cholangitis--what is the difference between east and west?World J Gastroenterol200814253974398118609680
- MalatyHMLoGHHouJKCharacterization and prevalence of spondyloarthritis and peripheral arthritis among patients with inflammatory bowel diseaseClin Exp Gastroenterol20171025926329026327
- RudwaleitMvan der HeijdeDLandewéRThe Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in generalAnn Rheum Dis2011701253121109520
- SandbornWJGasinkCGaoLLUstekinumab induction and maintenance therapy in refractory Crohn’s diseaseN Engl J Med2012367161519152823075178
- LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Lancet200837196251665167418486739
- PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet200837196251675168418486740
- WheatCLKoCWClark-SnustadKGrembowskiDThorntonTADevineBInflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysisBMC Gastroenterol20171715228407755
- PappKAGriffithsCEGordonKLong-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upBr J Dermatol2013168484485423301632
- FiorinoGDaneseSParienteBAllezMParadoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agentsAutoimmun Rev2014131151923777821
- MoranGWLimAWBaileyJLReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseAliment Pharmacol Ther20133891002102424099467